1. Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: A prospective cohort study.
- Author
-
Ding L, Guan L, Li X, Xu X, Zou Y, He C, Hu Y, Wan J, Huang X, Lei Y, He W, Xia L, Xiong H, Luo L, Lu N, and Zhu Y
- Subjects
- Adult, Humans, Prospective Studies, Acute Disease, Retrospective Studies, Triglycerides, Pancreatitis etiology, Hyperlipidemias complications, Hypertriglyceridemia
- Abstract
Background: Data on recurrent hypertriglyceridemia-induced acute pancreatitis (HTG-AP) are scarce., Objective: To investigate the incidence and risk factors for recurrence of HTG-AP, and the effect of triglyceride (TG) lowering drugs post index attack on recurrence., Methods: This study was a prospective cohort study of adult patients with first episode of HTG-AP from December 2019 to February 2021 who were followed until recurrence or death, or February 2022. The cumulative incidence function and Fine and Gray's competing-risk model were applied to the analyses., Results: A total of 317 patients were enrolled, and the 12-month and 18-month cumulative recurrence incidences were 8% and 22%, respectively. The cumulative recurrence incidence was 2 times higher in patients whose serum TG levels post index attack were ≥5.65 mmol/L (subdistribution hazard ratio [SHR], 2.00; 95% confidence interval [CI], 1.05-3.80; P = 0.034) compared to patients with TG <5.65 mmol/L. The recurrence rate was 3.3 times higher in patients whose glucose levels post index attack were ≥7.0 mmol/L (SHR, 3.31; 95% CI, 1.56-7.03; P = 0.002) than in patients with glucose <7.0 mmol/L). Compared to TG lowering drugs for less than 1 month post index attack, treatment for longer than 12 months decreased the incidence of recurrence by 75% (SHR, 0.25; 95% CI, 0.08-0.80; P = 0.019)., Conclusions: The HTG-AP recurrence incidence is high and closely associated with high levels of TGs and glucose post index attack. Long-term TG lowering drugs treatment significantly decreases this recurrence., Competing Interests: Declaration of Competing Interest None, (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF